Literature DB >> 2478651

Expression of a public idiotype by human monoclonal IgM directed to myelin-associated glycoprotein and characterization of the variability subgroup of their heavy and light chains.

J C Brouet1, K Dellagi, M C Gendron, A Chevalier, C Schmitt, E Mihaesco.   

Abstract

Most studies using rabbit or mouse antisera failed to detect CRI between human IgM directed to MAG. We show here that 9 of 10 such IgM express a public CRI as defined by a nonhuman primate antiserum. Shared idiotype is likely involved in (or close to) the combining site of those IgM since antiidiotypic serum inhibited the binding of IgM to MAG and reacted with IgM having different variable regions of light and heavy chains. Partial aminoterminal sequence of heavy and light chains showed that anti-MAG IgM use either lambda chains (one IgM) or kappa light chains (six IgM) of different variability subgroups (V kappa IV in three instances, V kappa I in two, and V kappa II in one), whereas heavy chains belong to the VHIII (six IgM) or to the VHII (1 IgM) subgroup. These features distinguish these IgM from other human monoclonal IgM with a defined antibody activity, such as rheumatoid factors or cold agglutinins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478651      PMCID: PMC2189509          DOI: 10.1084/jem.170.5.1551

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  20 in total

1.  A rapid procedure for selectively isolating the major glycoprotein from purified rat brain myelin.

Authors:  R H Quarles; C F Pasnak
Journal:  Biochem J       Date:  1977-06-01       Impact factor: 3.857

2.  The human anti-myelin-associated glycoprotein IgM system.

Authors:  N Murray; N Page; A J Steck
Journal:  Ann Neurol       Date:  1986-05       Impact factor: 10.422

3.  Antigenic specificities related to the cold agglutinin activity of gamma M globulins.

Authors:  R C Willims; H G Kunkel; J D Capra
Journal:  Science       Date:  1968-07-26       Impact factor: 47.728

4.  Investigation of the idiotypic determinants of IgM monoclonal proteins associated with neuropathy.

Authors:  S W Evans; N A Gregson; S L Leibowitz; N R Ling
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

5.  Specificity and idiotype of M-proteins that react with MAG in patients with neuropathy.

Authors:  T Saito; W H Sherman; N Latov
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

6.  IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside.

Authors:  A A Ilyas; R H Quarles; T D MacIntosh; M J Dobersen; B D Trapp; M C Dalakas; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

7.  Human monoclonal IgM autoantibodies with restricted antigenic specificity for myelin express unrelated idiotypes.

Authors:  S N Kahn
Journal:  J Neurol Sci       Date:  1985-07       Impact factor: 3.181

8.  Specificity of human IgM M-proteins that bind to myelin-associated glycoprotein: peptide mapping, deglycosylation, and competitive binding studies.

Authors:  M E Shy; T Vietorisz; E Nobile-Orazio; N Latov
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

9.  Distinct patterns of heavy chain variable region subgroup use by human monoclonal autoantibodies of different specificity.

Authors:  G J Silverman; F Goñi; J Fernandez; P P Chen; B Frangione; D A Carson
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

10.  A conserved human germline V kappa gene directly encodes rheumatoid factor light chains.

Authors:  V Radoux; P P Chen; J A Sorge; D A Carson
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

View more
  1 in total

1.  Monoclonal IgM from patients with peripheral demyelinating neuropathies cross-react with bacterial polypeptides.

Authors:  J C Brouet; X Mariette; M C Gendron; M L Dubreuil
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.